AbbVie (ABBV) PT Set at $98.00 by Credit Suisse Group

AbbVie (NYSE:ABBV) received a $98.00 price objective from stock analysts at Credit Suisse Group in a research report issued on Monday, January 22nd. The firm presently has a “hold” rating on the stock. Credit Suisse Group’s target price would indicate a potential downside of 13.34% from the company’s current price.

Other equities analysts have also recently issued research reports about the stock. Societe Generale boosted their price target on shares of AbbVie in a research report on Tuesday, November 21st. Argus upped their price objective on shares of AbbVie from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, September 29th. Jefferies Group restated a “buy” rating and issued a $107.00 price objective on shares of AbbVie in a report on Thursday, September 28th. Zacks Investment Research upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $102.00 price objective on the stock in a report on Tuesday, October 17th. Finally, BidaskClub cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. AbbVie currently has an average rating of “Buy” and a consensus target price of $117.26.

AbbVie (ABBV) traded up $1.22 during midday trading on Monday, hitting $113.08. 6,170,591 shares of the stock were exchanged, compared to its average volume of 7,360,000. AbbVie has a 52 week low of $60.15 and a 52 week high of $125.86. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. The company has a market cap of $180,520.00, a P/E ratio of 27.45, a P/E/G ratio of 1.06 and a beta of 1.61.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, January 26th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.44 by $0.04. AbbVie had a net margin of 18.82% and a return on equity of 152.78%. The business had revenue of $7.74 billion during the quarter, compared to the consensus estimate of $7.53 billion. During the same period in the previous year, the firm posted $1.20 earnings per share. The firm’s revenue for the quarter was up 13.9% on a year-over-year basis. sell-side analysts predict that AbbVie will post 7.46 earnings per share for the current fiscal year.

In related news, insider Laura J. Schumacher sold 145,510 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $96.71, for a total transaction of $14,072,272.10. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total transaction of $20,512,323.93. Following the transaction, the chairman now owns 492,030 shares in the company, valued at approximately $46,255,740.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 450,743 shares of company stock worth $43,153,684. Insiders own 0.23% of the company’s stock.

A number of institutional investors have recently modified their holdings of ABBV. Savant Capital LLC lifted its position in shares of AbbVie by 1.3% during the second quarter. Savant Capital LLC now owns 61,132 shares of the company’s stock worth $4,433,000 after purchasing an additional 793 shares in the last quarter. Princeton Capital Management Inc. bought a new position in shares of AbbVie during the 2nd quarter worth approximately $1,394,000. Palisade Asset Management LLC lifted its position in shares of AbbVie by 17.9% during the 2nd quarter. Palisade Asset Management LLC now owns 68,311 shares of the company’s stock worth $4,953,000 after buying an additional 10,381 shares during the period. Beaton Management Co. Inc. bought a new position in shares of AbbVie during the 2nd quarter worth approximately $528,000. Finally, Greatmark Investment Partners Inc. lifted its position in shares of AbbVie by 3.7% during the 2nd quarter. Greatmark Investment Partners Inc. now owns 35,178 shares of the company’s stock worth $2,551,000 after buying an additional 1,242 shares during the period. Institutional investors own 69.33% of the company’s stock.

TRADEMARK VIOLATION WARNING: “AbbVie (ABBV) PT Set at $98.00 by Credit Suisse Group” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/abbvie-abbv-given-a-98-00-price-target-by-credit-suisse-group-analysts.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply